Safety of intraarticular N-acetylglucosamine

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$845,835.00
Award Year:
2006
Program:
STTR
Phase:
Phase I
Contract:
1R42AT003352-01
Agency Tracking Number:
AT003352
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ARTYX PHARMACEUTICALS, INC.
ARTYX PHARMACEUTICALS, INC., 9025 BALBOA AVE, SUITE 110, SAN DIEGO, CA, 92123
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
MARTIN LOTZ
(858) 784-8960
MLOTZ@SCRIPPS.EDU
Business Contact:
(858) 736-6540
Research Institution:
SCRIPPS RESEARCH INSTITUTE

SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROAD
LA JOLLA, CA, 92037

Domestic nonprofit research organization
Abstract
DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy and can be associated with adverse reactions. This proposal is based on extensive prior work that identified N-acetylglucosamine (GlcNAc) as an agent with potential for both, symptom and disease modification in OA. GlcNAc has a spectrum of desirable activities in cell culture models and anti-inflammatory, analgesic and OA disease-modifying activity in animal models. The long-term goal of is to determine efficacy of repeated intraarticular injections of GlcNAc in the treatment of OA. Towards this goal we recently established safety of single intraarticular injections of up to 100mM GlcNAc in patients with knee OA. The next step and goal of the proposed STTR Phase I study is to establish safety of repetitive intraarticular injections of GlcNAc. Patients with knee OA will receive one injection of GlcNAc per week for three consecutive weeks. An escalating dosing scheme will be used including 1,10 and 100mM GlcNAc. Patients will be monitored for local and systemic adverse reactions.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government